• Active, Not enrolling

NCT03090659: Phase 1/2 - A Chinese study of LCAR-B38M CAR-T cells in RRMM -Myeloma (LEGEND-2)

Updated: Sep 2

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).

lcar-b38m

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)


A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients


Biological

LCAR-B38M CAR-T cell injection


Sponsor

Nanjing Legend Biotech Co.


Collaborators

Second Affiliated Hospital of Xi'an Jiaotong University

Ruijin Hospital

Jiangsu Provincial People's Hospital

Shanghai Changzheng Hospital


China


Legend Biotech

 

ClinicalTrials.gov Identifier: NCT03090659


Official Title: A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

 

CART - BCMA : National Cancer Institute

JNJ-68284528 - ciltacabtagene autoleucel

LCAR-B38M


JNJ-68284528

ciltacabtagene autoleucel

 

PMID: 30572922

J Hematol Oncol; Dec. 2018


A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma


 

CAR T-Cell Therapy in Multiple Myeloma Yields 100% Response Rate

Asco Post July, 2017

Click here for details



Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Meeting Abstract, ASCO 2017

Click here for details






Posts Archive